EXEL
USDExelixis Inc. Common Stock
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$37.810
고가
$38.900
저가
$37.582
거래량
2.81M
기업 기본 정보
시가총액
10.2B
산업
생명공학
국가
United States
거래 통계
평균 거래량
2.62M
거래소
NMS
통화
USD
52주 범위
관련 뉴스
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
- Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for
Guggenheim Downgrades Exelixis to Neutral
Guggenheim analyst Michael W. Schmidt downgrades Exelixis from Buy to Neutral.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are...
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after
Morgan Stanley Maintains Overweight on Exelixis, Lowers Price Target to $44
Morgan Stanley analyst Sean Laaman maintains Exelixis with a Overweight and lowers the price target from $50 to $44.
RBC Capital Reiterates Sector Perform on Exelixis, Maintains $45 Price Target
RBC Capital analyst Leonid Timashev reiterates Exelixis with a Sector Perform and maintains $45 price target.
Wells Fargo Maintains Equal-Weight on Exelixis, Lowers Price Target to $30
Wells Fargo analyst Derek Archila maintains Exelixis with a Equal-Weight and lowers the price target from $36 to $30.
